Efstathios Kastritis, MD, on Main Takeaways From Trial Examining Daratumumab Plus VCd to Treat AL Amyloidosis

Hematologic responses improved for patients treated with daratumumab plus VCd versus VCd alone in the ANDROMEDA trial.

CancerNetwork® had the opportunity to speak with Efstathios Kastritis, MD, at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting. The professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, detailed the overall takeaway of the phase 3 ANDROMEDA trial (NCT03201965), specifically how treatment with daratumumab (Darzalex) plus bortezomib, cyclophosphamide, and dexamethasone (VCd) improved outcomes for patients with newly diagnosed light chain (AL) amyloidosis.

Transcription:

We do have a very effective and relatively safe therapy for patients with AL amyloidosis, which has really and substantially improved the outcomes of our patients, [with] both complete hematologic response rates and organ responses, which is actually the ultimate goal of therapy in these patients. I really expect that this will be translated in an improvement in the overall survival in the follow up of this study.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. Presented at: 2021 ASCO Annual Meeting; June 4-8, 2021; Virtual. Abstract 8003.